NTRK1 and cancer: As a promising strategy for cancer treatment, recent studies have focused on the development of drugs for inhibiting receptor tyrosine kinases (RTKs), such as the epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), and the tropomyosin-related kinase (TRK) family [1].